Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alnylam Set To Bring 3rd Program Into Clinic; Continue Progress Of Other Two

Executive Summary

Alnylam plans to file an IND at FDA by the end of this year for a drug candidate to treat transthyretin-mediated amyloidosis (ATTR), with a goal of beginning Phase I study early next year, the biotech reported during an investor research and development presentation Nov. 12 (see chart: "1Alnylam's Aggressive Business Development Program Has Yielded Results")
Advertisement

Related Content

Alnylam CEO John Maraganore: An Interview With "The Pink Sheet" DAILY (Part 2 of 2)
Would AstraZeneca Be Better Off If Rezield Had Gotten A Harsher FDA Letter?
Would AstraZeneca Be Better Off If Rezield Had Gotten A Harsher FDA Letter?
AstraZeneca's MedImmune Comes Closer To Motavizumab Approval, And A Tight Grip On RSV Market
AstraZeneca's MedImmune Comes Closer To Motavizumab Approval, And A Tight Grip On RSV Market
Alnylam's Liver Cancer RNAi Program Enters The Clinic
Alnylam Takes Platform Monetization to a Whole New and Non-Exclusive Level

Topics

Advertisement
UsernamePublicRestriction

Register

PS051658

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel